Unveiling Paclitaxel-Induced Mesenchymal Stem Cells: orchestrating Nrf2 Modulation and Apoptosis in CD44+/CD24- Cancer Stem Cells
Syarifah S., Putra A., Muhar A.M., Hermansyah D.
Abstract
Background: Mesenchymal Stem Cells (MSCs) and Cancer Stem Cells (CSC) play pivotal roles in cancer progression and therapeutic responses. This study aimed to explored the effect of MSCs induced by paclitaxel on CSC expressing the CD44 +/CD24-phenotype, focusing on Nrf2 modulation and apoptosis induction. Methods: MSCs were characterized for adherence, differentiation potential, and surface markers via standard culture, staining assays, and flow cytometry, respectively. CSCs isolated from MDA-MB-231 using MACS and were characterized based on morphology and CD44+/CD24-expression. Co-culture experiments evaluated the cytotoxic effect of Paclitaxel-induced MSCs on CSC viability using MTT assays. Flow cytometry analysis assessed apoptosis induction via annexin V-PI staining and Nrf2 and Caspase-3 gene expression were measure by qRT-PCR analysis. Results: MSCs exhibited typical adherence and differentiation capabilities, confirming their mesenchymal lineage. CSCs displayed an elongated morphology and expressed CD44+/CD24-, characteristic of stem-like behavior. Paclitaxel induced dose-dependent Nrf2 gene expression in MSCs. Co-culture with Paclitaxel-induced MSCs reduced CSC viability in a dose-dependent manner, with a significant decrease observed at a 5:1 MSCs:CSC ratio. Co-culture decreased the Nrf2 gene expression and increased apoptosis in CSCs, with higher caspase-3 gene expression compared to solitary paclitaxel treatment. Conclusion: Paclitaxel-induced MSCs decreased Nrf2 expression and significantly decreased CSC viability while enhancing apoptosis. This suggests a potential strategy to mitigate paclitaxel resistance in CD44+/CD24-CSCs. Leveraging Paclitaxel-induced MSCs presents a promising avenue for targeting Nrf2 and promoting apoptosis in CSCs, potentially improving the efficacy of chemotherapy and addressing resistance mechanisms in cancer treatment.
Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1
Bian C., Han Q., Li J., Liao L., Liu Y., Shao C., Sun Z., Wang J., Yan X., Zhao R.C., Zhu Y.
Wnt signaling in the tumor microenvironment
Gang E., Kim H.N., Kim Y.-M., Ogana H., Ruan Y., Ruan Y.
Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway
Bu F., Chen H., Chen H., Ding Y., Hu J., Li T., Liu K., Qi W., Sun L., Sun X., Tu T., Zhai W., Zhang C., Zhou F., Zhu W.
Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway
Cao Z., Chen G., Hu Y., Lu L., Lu L., Lu Y., Ma Z., Wang X., Wang X., Wang Y., Yang J., Yang Y.
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy
Capilla-Gonzalez V., Gauthier B.R., Gauthier B.R., Hmadcha A., Hmadcha A., Martin-Montalvo A., Soria B., Soria B., Soria B.
Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies
Fang Y., Li Y.-R., Lyu Z., Yang L., Yang L., Zhu Y.
Role of msc in the tumor microenvironment
Hass R.
The intricacies of NRF2 regulation in cancer
Chapman E., Dodson M., Schmidlin C.J., Shakya A., Zhang D.D., Zhang D.D.
An update of Nrf2 activators and inhibitors in cancer prevention/promotion
Dadashpour M., Jeddi F., Pouremamali A., Pouremamali F., Soozangar N.
Therapeutic targeting of the NRF2 signaling pathway in Cancer
Cevik D., Panieri E., Saso L., Suzen S., Telkoparan-Akillilar P.
Wei Z., Xing Q., Ding H., Wang J., Yu Z., Dong L., Xu X., Tang H., Li Z., Jiang X.
Stem Cells International
Current Issues in Molecular Biology
